SCHEMBL5842943

SCHEMBL5842943

Cc1cc(C)nc(N(C)c2ccc(NC(=O)C3CC(=O)N(CCc4cccs4)C3)cc2)n1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXFP3 Q9NSD7 5/20 0.51
ALDH1A1 P00352 7/20 0.45
HTT P42858 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 2/20 0.43
PKM P14618 1/20 0.42
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 2/20 0.41
MCL1 Q07820 1/20 0.41
HIF1A Q16665 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5843190 0.90 RXFP3 (0.50) RXFP3ALDH1A1HTTL3MBTL1LMNA
SCHEMBL5843753 0.86 RXFP3 (0.56) RXFP3ALDH1A1HTTL3MBTL1LMNA
SCHEMBL5842690 0.86 SMN1; SMN2 (0.57) RXFP3ALDH1A1HTTL3MBTL1LMNA
SCHEMBL6612748 0.86 RXFP3 (0.38) RXFP3ALDH1A1L3MBTL1LMNASMN1; SMN2
SCHEMBL5842936 0.85 RXFP3 (0.53) RXFP3ALDH1A1HTTL3MBTL1LMNA
SCHEMBL5843197 0.84 RXFP3 (0.52) RXFP3ALDH1A1HTTL3MBTL1LMNA
SCHEMBL5843202 0.84 RXFP3 (0.51) RXFP3ALDH1A1HTTL3MBTL1LMNA
SCHEMBL5841935 0.84 ALDH1A1 (0.47) ALDH1A1HTTL3MBTL1LMNASMN1; SMN2
SCHEMBL5841229 0.81 ALDH1A1 (0.68) RXFP3ALDH1A1HTTL3MBTL1LMNA
SCHEMBL5841192 0.80 MAPT (0.69) RXFP3ALDH1A1HTTL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067549-B2 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2006-06-27 US disclosed
US-20050192292-A1 Pyrrolidone carboxamides ACTELION PHARMACEUTICALS AG (CH) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192292-A1 Pyrrolidone carboxamides NPY1R, NPY5R, NPY2R RXFP3 52/4885ALDH1A1 3034/4885HTT 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.